Plus Therapeutics, Inc. (PSTV)
NASDAQ: PSTV · Real-Time Price · USD
0.5298
-0.0667 (-11.18%)
At close: Jul 25, 2025, 4:00 PM
0.5252
-0.0046 (-0.87%)
After-hours: Jul 25, 2025, 7:59 PM EDT
Plus Therapeutics Revenue
Plus Therapeutics had revenue of $1.06M in the quarter ending March 31, 2025, a decrease of -36.85%. This brings the company's revenue in the last twelve months to $5.21M, down -14.43% year-over-year. In the year 2024, Plus Therapeutics had annual revenue of $5.82M with 18.54% growth.
Revenue (ttm)
$5.21M
Revenue Growth
-14.43%
P/S Ratio
0.94
Revenue / Employee
$247,905
Employees
21
Market Cap
32.05M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 5.82M | 911.00K | 18.54% |
Dec 31, 2023 | 4.91M | 4.69M | 2,093.30% |
Dec 31, 2022 | 224.00K | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | 303.00K | -6.70M | -95.67% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
Novartis AG | 55.19B |
AstraZeneca | 54.98B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
PSTV News
- 3 days ago - Plus Therapeutics Announces $1.6 Million Advance Payment from CPRIT - GlobeNewsWire
- 11 days ago - Plus Therapeutics Presents ReSPECT-LM Clinical Trial Results for REYOBIQ™ in Patients with Leptomeningeal Metastases - GlobeNewsWire
- 16 days ago - Plus Therapeutics Announces Two CNSide Presentations at the Upcoming SNO/ASCO CNS Metastases Conference - GlobeNewsWire
- 18 days ago - Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases - GlobeNewsWire
- 26 days ago - Plus Therapeutics Announces FDA Agreement to Initiate ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases - GlobeNewsWire
- 4 weeks ago - Plus Therapeutics Provides Business Update on CNSide Diagnostics Subsidiary - GlobeNewsWire
- 4 weeks ago - Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, June 26, 2025 at 9:00 A.M. ET - GlobeNewsWire
- 4 weeks ago - Plus Therapeutics Announces FDA Clearance of its Investigational New Drug Application using REYOBIQTM for the Treatment of Childhood Brain Cancer - GlobeNewsWire